Drug Search Results
Using advanced filters...
Advanced Search [+]

CHF-5259

Alternative Names: chf-5259, chf5259, chf 5259
Latest Update: 2024-09-04
Latest Update Note: Clinical Trial Update

Product Description

For Chronic Obstructive Pulmonary Disease

Mechanisms of Action: M3 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Chiesi
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma|Chronic Obstructive Pulmonary Disease

Phase 1: Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2019-002238-35

P2

Completed

Asthma

2021-02-04

GLIMMER

P2

Completed

Chronic Obstructive Pulmonary Disease

2018-05-23

73%

2015-000558-40

P2

Completed

Chronic Obstructive Pulmonary Disease

2017-02-06

GlycoNEXT

P2

Completed

Chronic Obstructive Pulmonary Disease

2017-02-06

CCD-06302AA1-02

P1

Completed

Chronic Obstructive Pulmonary Disease

2016-08-01

ELITRA

P2

Completed

Asthma

2015-08-13

ELITRA

P2

Completed

Asthma

2015-08-01

TRISKEL

P2

Completed

Asthma

2015-03-08

Triskel

P2

Completed

Asthma

2015-03-01

2013-005268-25

P2

Completed

Chronic Obstructive Pulmonary Disease

2015-02-06

Trigon

P2

Completed

Chronic Obstructive Pulmonary Disease

2015-02-01

Recent News Events

Date

Type

Title